
Natasha Hunter, MD
Advertisement
Articles by Natasha Hunter, MD


24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

Experts provide perspective on the rapidly changing landscape of targeted therapies in breast cancer treatment, and the importance of matching the right agent with the right patient.
Advertisement
Latest Updated Articles
The Changing Landscape of Targeted Breast Cancer TherapiesPublished: April 10th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC
2
FDA Approves Liquid Biopsy CDx for Encorafenib Regimen in BRAF V600E+ CRC
3
BNT113 Granted Fast Track Designation in HPV16-Positive HNSCC
4
Decoding the Top Moments in Prostate Cancer Management From 2025
5

